The Fourth International Conference on VZV











March 3-5, 2001
Hilton La Jolla Torrey Pines
La Jolla, California

Presented by the
VZV Research Foundation
in partnership with
Columbia University College of Physicians & Surgeons

CONFERENCE GOALS AND OBJECTIVES

  • Promote a better understanding of varicella and herpes zoster;
  • Present the current experience with and the future potential of vaccines to prevent varicella and herpes zoster;
  • Define treatment options for varicella and herpes zoster; and,
  • Develop a better understanding of zoster pain and post-herpetic neuralgia and their managment.

CONFERENCE SUPPORTERS
The VZV Research Foundation is grateful to the following corporations and foundation who provided unrestricted, educational grants in support of this conference:

THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY
MERCK & CO., INC.
THE R.W. JOHNSON PHARMACEUTICAL
RESEARCH INSTITUTE
PHARMACIA CORPORATION
PFIZER INC.
GLAXOSMITHKLINE
ENDO PHARMACEUTICALS INC.
NATIONAL INSTITUTE ON AGING
NOVARTIS PHARMACEUTICALS CORPORATION

CANGENE CORPORATION


ORAL PRESENTATION ABSTRACTS
INDEX
[1A]
STUDY OF SHINGLES AND ITS DEVELOPMENT TO POSTHERPETIC NEURALGIA IN EAST LONDON

[1B]
ZOSTER ASSOCIATED PAIN IN HEALTHY AND IMMUNOCOMPROMISED SUBJECTS FOLLOWING SHINGLES
[1C]
VIROLOGICAL EVIDENCE TO IDENTIFY PATIENTS AT HIGH RISK OF ZAP PERSISTING FOLLOWING SHINGLES
[2]
GEOGRAPHIC AND RACIAL ASPECTS OF HERPES ZOSTER: THE FAMCICLOVIR DATABASE PROJECT
[3]
VARICELLA ZOSTER VIRUS (VZV) CELL MEDIATED IMMUNITY (CMI)
IN HIV-INFECTED PATIENTS ON HIGHLY AFFECTIVE
ANTIRETROVIRAL THERAPY (HAART)
[4A]
EVALUATION OF A MODIFIED BRIEF PAIN INVENTORY TO MEASURE PAIN ASSOCIATED WITH HERPES ZOSTER
[4B]
THE VALIDITY OF A MEASURE OF THE SEVERITY AND DURATION OF HERPES ZOSTER PAIN
[5]
APPLICATION OF A NEW PHASE-SPECIFIC MODEL IN THE EVALUATION OF HERPES ZOSTER PAIN
[6]
TRANSITION OF ACUTE HERPETIC PAIN FROM SYMPATHETICALLY DEPENDENT PAIN INTO SYMPATHETICALLY INDEPENDENT PAIN
[7]
PREVENTION OF POST-HERPETIC NEURALGIA
[8]
SURGICAL REMOVAL OF PAINFUL POST-HERPETIC SKIN AND ANALYSIS OF CUTANEOUS INNERVATION - A CASE REPORT

[9]
TOPICAL LIDOCAINE PATCH (LIDODERM®) PRODUCES A SIGNIFICANT IMPROVEMENT IN QUALITY OF LIFE INDICATORS IN TREATED PHN PATIENTS: RESULTS OF A MULTICENTER OPEN-LABEL TRIAL
[10]
The Gladys T. Perkin Lecture

OCULAR COMPLICATIONS OF VZV
[11]
DECLINE IN VARICELLA INCIDENCE AND HOSPITALIZATIONS IN SENTINEL SURVEILLANCE AREAS IN THE UNITED STATES, 1995-2000.

[12]
EPIDEMIOLOGY OF VARICELLA ZOSTER VIRUS INFECTION IN CANADA AND THE UNITED KINGDOM
[13]
THE CLINICAL, SOCIAL AND ECONOMIC BURDEN OF CHICKENPOX IN A DEVELOPED COUNTRY
[14]
HOSPITALIZATIONS FOR VARICELLA IN THE UNITED STATES IN THE PRE-VACCINATION ERA, 1988-1995
[15]
GENETIC VARIATION OF VARICELLA ZOSTER VIRUS
[16]
MOLECULAR VARIABILITY AMONG GEOGRAPHICALLY DISTINCT ISOLATES OF VARICELLA-ZOSTER VIRUS.
[17]
VARICELLA SUSCEPTIBILITY AMONG MEXICAN AND AMERICAN ADULTS
[18]
VARICELLA SEROPREVALENCE IN THE US POPULATION, NHANES III,
1988-1994
[19]
DEVELOPMENT OF AN INTERFERON-y ELISPOT ASSAY FOR QUANTITATION OF CELLULAR IMMUNE RESPONSES TO VZV
[20]
VARICELLA-ZOSTER VIRUS (VZV)-SPECIFIC CELL-MEDIATED IMMUNITY MEASURED BY RESPONDER CELL FREQUENCY AND ELISPOT ASSAY IN ELDERLY SUBJECTS RECEIVING MULTIPLE DOSES OF A VZV VACCINE
[21]
VACCINATION OF 12-YEARS OLD VARICELLA HISTORY NEGATIVE
SCHOOL-CHILDREN WITH VZV-VACCINE CONCOMITANT WITH MMR-VACCINATION IN STOCKHOLM, SWEDEN.
[22]
THE SHINGLES PREVENTION STUDY: AN UPDATE
[23]
VARICELLA SUSCEPTIBILITY AND VACCINE USE AMONG YOUNG ADULTS ENLISTING IN THE UNITED STATES NAVY
[24]
ESTIMATION OF VARICELLA VACCINE EFFICACY
[25A]
OKA/MERCK VARICELLA VACCINE: PERSISTENCE OF ANTIBODY, DURATION OF PROTECTION, AND VACCINE EFFICACY
[25B]
EFFICACY OF OKA/MERCK VARICELLA VACCINE AFTER CONCOMITANT ADMINISTRATION WITH M-M-R®II
[25C]
CHILDHOOD VACCINATION WITH OKA/MERCK VARICELLA VACCINE: CORRELATION OF 6-WEEK POSTVACCINATION VARICELLA ANTIBODY RESPONSE DETERMINED BY gp-ELISA WITH PROTECTION AGAINST BREAKTHROUGH INFECTION
[25D]
PREDICTION OF POSTVACCINATION VARICELLA BREAKTHROUGH RATES BASED ON THE VARICELLA ANTIBODY DETERMINED BY
gp-ELISA 6 WEEKS POSTVACCINATION
[26]
A COMBINED MEASLES, MUMPS, RUBELLA AND VARICELLA CANDIDATE VACCINE
[27]
VARICELLA-ZOSTER VIRUS ORF2 IS NOT REQUIRED FOR REPLICATION IN CELL CULTURE OR FOR ESTABLISHMENT OF LATENCY
[28]
VZV GLYCOPROTEIN I IS IMPORTANT BUT NOT ESSENTIAL FOR THE TRAFFICKING AND SURFACE EXPRESSION OF GLYCOPROTEIN E
[29]
VARICELLA-ZOSTER VIRUS FUSION IS MEDIATED BY GLYCOPROTEINS gH, gL AND gB BUT ENHANCED BY gE
[30]
TRANSCRIPTIONAL PATTERN OF VARICELLA-ZOSTER VIRUS GLYCOPROTEINS E AND I
[31]
GENOMICS OF VZV-MSP: AN ANALYSIS OF SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) IN THE VZV GENOME
[32]
PHOSPHORYLATION OF VZV REGULATORY AND STRUCTURAL PROTEINS BY A CLONED, BIOLOGICALLY ACTIVE ORF47 PROTEIN KINASE
[33]
CELLULAR FACTORS AND IE62 ACTIVATION OF VZV PROMOTERS
[34]
INSIGHTS INTO VZV TRANSCRIPTIONAL CONTROL: THE USF-BINDING PROMOTER ELEMENT IN VZV GENE 4 IS REQUIRED FOR EFFICIENT ACTIVITY IN THE CONTEXT OF THE GENOME
[35]
VZV REPLICATION IN VITRO IS PREVENTED BY ROSCOVITINE, AN INHIBITOR OF THE CELL CYCLE
[36]
LATENT AND LYTIC INFECTION OF ISOLATED GUINEA PIG ENTERIC NEURONS BY VARICELLA ZOSTER VIRUS (VZV)

[37]
INDUCED NORADRENALINE SENSITIVITY OF SENSORY NEURONS FROM RAT DORSAL ROOT GANGLIA AFTER INFECTION WITH HUMAN VARICELLA ZOSTER VIRUS
[38]
VIRAL GENE EXPRESSION DURING ACUTE SIMIAN VARICELLA VIRUS INFECTION
[39]
INFECTIBILITY OF SEPARATED PERIPHERAL BLOOD MONONUCLEAR
CELLS (PBMC) SUBPOPULATIONS WITH CELL-FREE VARICELLA-ZOSTER VIRUS (VZV)
[40]
POLYMORPHISM OF THE INTERLEUKIN-10 GENE IS ASSOCIATED WITH SUSCEPTIBILITY TO HERPES ZOSTER
~~~~~~~~~~
POSTER PRESENTATION ABSTRACTS
INDEX
[41]
DIFFERENTIAL DIAGNOSIS OF ACUTE HERPES ZOSTER
[42]
HERPES ZOSTER IN JAPANESE ELDERLY PEOPLE
[43]
GENERALIZED ZOSTER IN A 16-YEAR-OLD AFTER BMT FOR LEUKEMIA
[44]
CURRENT STATUS AND ISSUES OF CHRONIC PAIN IN HERPES ZOSTER BASED ON SURVEYS OF PATIENTS AND PHYSICIANS
[45]
A RANDOMIZED DOUBLE-BLIND SURVEY ON THE EFFECT OF BRIVUDIN IN THE PREVENTION OF POSTHERPETIC PAIN IN COMPARISON WITH ACYCLOVIR
[46]
BRIVUDIN COMPARED TO FAMCICLOVIR IN THE PREVENTION OF POSTHERPETIC NEURALGIA: A RANDOMIZED, DOUBLE-BLIND MULTICENTER TRIAL
[47]
BRIVUDIN COMPARED TO ACYCLOVIR IN THE TREATMENT OF ACUTE HERPES ZOSTER: A RANDOMIZED; DOUBLE-BLIND, MULTICENTER TRIAL
[48]
EFFECTS OF NEUROTROPIN® ON POST-HERPETIC NEURALGIA:
DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL
[49]
NEUROTROPIN® MODULATES ALLODYNIA AND HYPERALGESIA INDUCED BY HSV-1 INFECTION: A POSSIBLE TREATMENT TO ZOSTER-ASSOCIATED PAIN
[50]
SUCCESSFUL LONG-TERM TREATMENT OF PAIN IN POST-HERPETIC NEURALGIA WITH THE VENOM OF APIS MELLIFERA
[51]
TOWARDS AN ALGORITHM FOR MANAGEMENT OF PHN
[52]
PRO AND CONS OF UNIVERSAL VARICELLA VACCINATION IN EUROPE:
THE EUROVAR INITIATIVE
[53]
PREVALENCE OF ANTIBODIES TO VARICELLA-ZOSTER VIRUS IN THE GERMAN POPULATION
[54]
IMMUNIZATION OF CHILDREN WITH LIVE VARICELLA VACCINE BY INTRANASAL ROUTE: IMMUNE RESPONSE AND CLINICAL REACTION
[55]
COST-EFFECTIVENESS OF VARICELLA VACCINATION IN CANADA
[56]
THE EPIDEMIOLOGY OF HERPES ZOSTER AND POTENTIAL
COST-EFFECTIVENESS OF VACCINATION IN ENGLAND AND WALES

[57]
MODELLING THE IMPACT OF VARICELLA VACCINATION ON THE EPIDEMIOLOGY OF VARICELLA AND ZOSTER
[58]
VARICELLA EPIDEMIOLOGY IN GERMANY FOR HEALTH ECONOMIC ANALYSES
[59]
COMPARISON OF THE VARICELLA ANTIBODY RESPONSE AFTER VACCINATION WITH EITHER OKA/MERCK VARICELLA VACCINE OR VARILRIX TM (SB BIO (OKA-RIT))
[60]
DEVELOPMENT OF AN ENZYME LINKED IMMUNOSORBENT ASSAY FOR THE DETECTION OF IgG ANTIBODIES TO VARICELLA ZOSTER VIRUS IN ORAL FLUID SAMPLES
[61]
MEASUREMENT OF CELL-MEDIATED IMMUNE-RESPONSE TO VZV USING FLOW CYTOMETRIC ANALYSIS OF ACTIVATED WHOLE-BLOOD
[62]
ANALYSIS OF THE VZV ORF63 PROTEIN
[63]
CHARACTERIZATION OF THE VIRAL HIGHWAYS OF VARICELLA ZOSTER VIRUS INFECTED CELLS
[64]
FRACTIONATION OF NEURONS AND SATELLITE CELLS FROM HUMAN SENSORY GANGLIA IN ORDER TO STUDY HERPESVIRUS LATENCY
[65]
UITRASTRUCTURAL STUDY ON THE HOST RELATIONSHIP AND AFFINITY BETWEEN VZV AND DIFFERENT CELLS IN LESIONS OF PATIENTS WITH VARICELLA AND HERPES ZOSTER
[66]
GENOTYPING OF VARICELLA-ZOSTER VIRUS IN CANADA: 1900-2000
[67]
CLINICAL VARICELLA-ZOSTER VIRUS ISOLATE WITH A MUTATION IN THE 3B3 MONOCLONAL ANTIBODY EPITOPE OF GLYCOPROTEIN E
 

About VZVRF
| What's New | Q & A

Patient Information | Physicians/Scientists | La Jolla Conference | EuroVar | Ganglia Bank | Show Your Support | Media Relations | Disclaimer



2001 VZV Research Foundation